UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000021303
Receipt number R000024520
Scientific Title Feasibility of Cytoreductive Prostatectomy in Men Newly Diagnosed with Metastatic Prostate Cancer
Date of disclosure of the study information 2016/04/01
Last modified on 2020/08/20 11:00:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Feasibility of Cytoreductive Prostatectomy in Men Newly Diagnosed with Metastatic Prostate Cancer

Acronym

Feasibility of Cytoreductive Prostatectomy

Scientific Title

Feasibility of Cytoreductive Prostatectomy in Men Newly Diagnosed with Metastatic Prostate Cancer

Scientific Title:Acronym

Feasibility of Cytoreductive Prostatectomy

Region

Japan Asia(except Japan) North America


Condition

Condition

metastatic prostate cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To determine the safety and feasibility of cytoreductive prostatectomy in men with newly diagnosed clinical T1-3N1M0 or T1-3N0M1a-b prostate cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase I,II


Assessment

Primary outcomes

the rate of major peri-operative complications (Clavien-Dindo grade
III or higher, please see appendix A) that occur within 90 days after cytoreductive
prostatectomy.

Key secondary outcomes

1) time to PSA nadir and 2) time to rising PSA while on standard systemic therapy.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Patients deemed to have cT3 or less will be offered the Robotic Assisted Radical Prostatectomy (RARP).

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

1 Histologically proven adenocarcinoma of the prostate.
2 Evidence of lymph node or bone metastasis by MRI/CT, bone scan, or biopsy
(N1Mx or NxM1).
3 Give informed consent.
4 Clinical stage T3 or less (pelvic MRI or CT scan shows no rectal and ureteral
invasion).
5 Must be male and 18 years or older
6 Cleared by the primary medical doctor for surgery.
7 ECOG Performance Status of 0 or 1.

Key exclusion criteria

1 Males under the age of 20.
2 Refuses to give informed consent.
3 Refuses or is unable to have pelvic MRI or CT scan.
4 Clinical stage T4 (pelvic MRI shows rectal and/or ureteral invasion).
5 Deemed a poor surgical risk per primary medical doctor.
6 Known spinal cord compression or brain or liver metastasis or any other visceral
metastases.
7 DVT/PE in the past 6 months

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Shigeo
Middle name
Last name Horie

Organization

Juntendo University Hospital

Division name

Dept. of Urology

Zip code

1138431

Address

3-1-3 Hongo Bunkyo-ku, Tokyo, Japan

TEL

+81-3-3813-3111

Email

shorie@juntendo.ac.jp


Public contact

Name of contact person

1st name Masayoshi
Middle name
Last name Nagata

Organization

Juntendo University Hospital

Division name

Dept. of Urology

Zip code

1138431

Address

3-1-3 Hongo Bunkyo-ku, Tokyo, Japan

TEL

+81-3-5802-1227

Homepage URL


Email

m-nagata@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University, Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

health insurance

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

Rutgers Cancer Institute of New Jersey, University of Pennsylvania (Philadelphia, PA), Temple University (Philadelphia, PA), City of Hope (Duarte, CA), University of California at Irvine (Orange, CA),
Swedish Medical Center (Seattle, WA), Seoul National University Bundang Hospital (Seoul, Korea)

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Juntendo University Ethics Committee

Address

3-1-3 Hongo Bunkyo-ku, Tokyo, Japan

Tel

03-3813-3111

Email

jun-rinri@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

Rutgers Cancer Institute of New Jersey, University of Pennsylvania (Philadelphia, PA), Temple University (Philadelphia, PA), City of Hope (Duarte, CA), University of California at Irvine (Orange, CA), Swedish Medical Center (Seattle, WA), Seoul National University Bundang Hospital (Seoul, Korea)


Other administrative information

Date of disclosure of the study information

2016 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 01 Month 20 Day

Date of IRB

2020 Year 01 Month 31 Day

Anticipated trial start date

2016 Year 04 Month 01 Day

Last follow-up date

2018 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 03 Month 02 Day

Last modified on

2020 Year 08 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024520